Adhera Therapeutics Inc ATRX
$0.00
Last Updated: Jul 31, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
Adhera Therapeutics Inc. Stock Analysis ATRX
United States Health Care Nano Cap Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company is headquartered in Wake Forest, North Carolina. The firm is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The firm has two drug candidates: MLR-1019 and MLR-1023. The company is engaged in developing MLR-1023 (tolimidone) as a new drug for Type I Diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated clinical safety and tolerability in over 700 patients in Phase IIa and Phase IIb Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease.
Adhera Therapeutics Inc (ATRX) Chart
Financial Metrics & Statements of Adhera Therapeutics Inc (ATRX)
FAQ's for Adhera Therapeutics Inc (ATRX)
- As of August 2026, Adhera Therapeutics Inc ATRX is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Adhera Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Adhera Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Adhera Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Adhera Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Adhera Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Adhera Therapeutics Inc (ATRX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
